BioSyent Announces Financial Results for Last Three and Nine Months

BioSyent Inc. (CVE:RX) reported its financial results for the three and nine months ending Sept. 30, 2015.
Some highlights from the report include:

– Third quarter (Q3) 2015 Revenues of $4,646,236 increased by 28% versus Q3 2014
– First nine months (YTD) 2015 Revenues of $11,546,334 increased by 26% versus YTD 2014
– YTD 2015 Pharmaceutical Revenues of $10,633,525 increased by 28% versus YTD 2014
– YTD 2015 Net Revenues have grown at a compound annual growth rate (CAGR) of 43% over the corresponding previous two years
– Q3 2015 EBITDA(1) of $1,619,701 increased by 20% over Q3 2014
– YTD 2015 EBITDA of $4,110,130 increased by 27% over YTD 2014
– Q3 2015 Net Income After Tax of $1,188,536 increased by 19% versus Q3 2014
– YTD 2015 Net Income After Tax of $3,002,287 increased by 25% over YTD 2014 — Q3 2015 Fully Diluted EPS was $0.08 as compared to $0.07 in the prior year period

Click here to read the full press release.